Thrivent Financial for Lutherans Raises Stake in Amneal Pharmaceuticals, Inc. $AMRX

Thrivent Financial for Lutherans boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 60.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 92,684 shares of the company’s stock after buying an additional 35,076 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Amneal Pharmaceuticals were worth $927,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AMRX. Exchange Traded Concepts LLC bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at approximately $31,000. Truist Financial Corp bought a new position in Amneal Pharmaceuticals during the third quarter valued at $137,000. Inceptionr LLC purchased a new stake in Amneal Pharmaceuticals in the second quarter worth $115,000. State of Tennessee Department of Treasury bought a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $133,000. Finally, Whalen Wealth Management Inc. purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $135,000. Institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AMRX shares. Barclays initiated coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Truist Financial set a $15.00 price objective on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $13.80.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $14.82 on Monday. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $15.00. The stock has a market capitalization of $4.66 billion, a PE ratio of 741.37 and a beta of 1.36. The company’s 50 day simple moving average is $13.28 and its two-hundred day simple moving average is $11.32.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.